Michael Cherny
Stock Analyst at B of A Securities
(5.00)
# 5
Out of 4,876 analysts
111
Total ratings
56.1%
Success rate
138.68%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAH Cardinal Health | Maintains: Buy | $165 → $170 | $167.15 | +1.71% | 12 | Jun 10, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.05 | +185.71% | 2 | May 28, 2025 | |
| MCK McKesson | Maintains: Buy | $755 → $800 | $725.61 | +10.25% | 13 | May 9, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $19.60 | +17.35% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $310.24 | +6.37% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $49.78 | -19.65% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $68.41 | +9.63% | 11 | Feb 13, 2025 | |
| PGNY Progyny | Maintains: Buy | $21 → $25 | $21.68 | +15.31% | 10 | Feb 11, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $61.00 | +47.54% | 2 | Feb 7, 2025 | |
| ALGN Align Technology | Upgrades: Outperform | $235 → $280 | $188.41 | +48.61% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $135 → $174 | $177.42 | -1.93% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $72.96 | +15.13% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $157.15 | +57.81% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $144.80 | +76.10% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $15.87 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $299.09 | -8.05% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $23 → $22 | $11.43 | +92.48% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $260.19 | -0.07% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $23 | $21.61 | +4.12% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.87 | +64.44% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $11.39 | +66.81% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $8.43 | +101.66% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $5.70 | +821.05% | 2 | Jan 5, 2022 |
Cardinal Health
Jun 10, 2025
Maintains: Buy
Price Target: $165 → $170
Current: $167.15
Upside: +1.71%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.05
Upside: +185.71%
McKesson
May 9, 2025
Maintains: Buy
Price Target: $755 → $800
Current: $725.61
Upside: +10.25%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $19.60
Upside: +17.35%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $310.24
Upside: +6.37%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $49.78
Upside: -19.65%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $68.41
Upside: +9.63%
Progyny
Feb 11, 2025
Maintains: Buy
Price Target: $21 → $25
Current: $21.68
Upside: +15.31%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $61.00
Upside: +47.54%
Align Technology
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $188.41
Upside: +48.61%
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $177.42
Upside: -1.93%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $72.96
Upside: +15.13%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $157.15
Upside: +57.81%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $144.80
Upside: +76.10%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $15.87
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $299.09
Upside: -8.05%
Mar 18, 2024
Maintains: Market Perform
Price Target: $23 → $22
Current: $11.43
Upside: +92.48%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $260.19
Upside: -0.07%
Feb 26, 2024
Initiates: Market Perform
Price Target: $23
Current: $21.61
Upside: +4.12%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $4.87
Upside: +64.44%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $11.39
Upside: +66.81%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $8.43
Upside: +101.66%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $5.70
Upside: +821.05%